Annovis Bio posted a net loss of $7.26 million in Q3 2025, a significant improvement from $12.64 million in the same period last year. R&D expenses rose sharply as the company progressed its Phase 3 Alzheimer's trial, while G&A costs declined.

In Q2 2025, Annovis Bio lowered its operating expenses and narrowed its net loss compared to the previous year. The company continued to invest in its pivotal Phase 3 trial for Alzheimer's and expanded its IP portfolio. A stronger balance sheet supported its operational momentum, backed by improved cash reserves.

Annovis Bio, Inc. experienced a net loss of $5.54 million in Q1 2025, an increase from the $1.07 million net loss in Q1 2024. The company's operating loss was $6.28 million, an improvement from $7.81 million in the prior year. Research and development expenses decreased, while interest income significantly increased due to higher cash balances from a public offering.

Annovis Bio made significant progress in 2024, advancing its buntanetap program with successful completion of two clinical trials and FDA clearance for a pivotal Phase 3 trial in early AD. The company reported a net loss of $5.86 million for Q4 2024, an improvement from the previous year, and ended the year with increased cash and cash equivalents.

Annovis Bio reported its third quarter financial results, highlighting the FDA's approval to initiate confirmatory Phase 3 studies for early Alzheimer's disease and the strengthening of their intellectual property portfolio with new patents for buntanetap combinations.